Arca
Skip to content

Graft vs host disease

Drug research and approvals for graft vs host disease: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 16, 2026, 203 studies of graft vs host disease are recruiting on ClinicalTrials.gov, Health Canada has authorized 24 drug trials for it since 2013, FDA has 0 approved and 1 open orphan designations naming it, and the EU has 1 authorised medicine for it.

  • Recruiting worldwide: 203
  • Trials authorized in Canada: 24
  • FDA orphan approvals: 0
  • EU medicines: 1

Recruiting Now

Newest start dates first, of 203 recruiting on ClinicalTrials.gov ↗

Trials Authorized in Canada

The 10 newest of 24; search them all in Canada trials
Jul 16, 2025An open-label, phase 1/2, multicenter study of belumosudil in children aged 1 to <18 years requiring systemic treatment for active moderate-to-severe chronic…BELUMOSUDIL (SAR445761)SANOFI-AVENTIS CANADA INCPending
Sep 25, 2024A phase 3, randomized, double-blind, placebo-controlled study of axatilimab and corticosteroids as initial treatment for chronic graft versus-host diseaseAXATILIMABIncyte CorporationOngoing
Jun 27, 2024An open label, multi-center, phase IV rollover protocol for patients who have completed a prior global novartis or incyte sponsored ruxolitinib (inc424) study…RUXOLITINIB (INC424)Novartis Pharmaceuticals CorporationOngoing
May 29, 2024A phase 2, open-label, randomized, multicenter study to evaluate the safety and efficacy of axatilimab in combination with ruxolitinib in participants with…AXATILIMAB/ RUXOLITINIBIncyte CorporationOngoing
Oct 26, 2023A randomized, double-blind, multicenter, phase 3 study to evaluate efficacy and safety of belumosudil in combination with corticosteroids versus placebo in…BELUMOSUDIL (SAR445761)SANOFI-AVENTIS CANADA INCOngoing
Aug 4, 2023Serial response and biomarker-guided steroid taper for children with gvhdPREDNISONETHE HOSPITAL FOR SICK CHILDRENClosed
May 1, 2023A phase Ib, open-label, randomized, dose-finding, multicenter study to evaluate the safety, pharmacokinetics, and efficacy of gdc-8264 in combination with…RO7288817 (GDC-8264)RocheClosed
Mar 17, 2022A phase 3, randomized, double-blind, placebo- controlled multicenter study of itolizumab in combination with corticosteroids for the initial treatment of acute…ITOLIZUMABEQUILLIUM, INC.Ongoing
Mar 4, 2021A randomized, open-label phase II clinical trial comparing durable overall response rate (dor) at 56 days in patients with steroid-resistant severe acute gvhd…HUMAN PLACENTA DERIVED DECIDUAL STROMAL CELLS (DSC)UNIVERSITY HEALTH NETWORKOngoing
Dec 18, 2020A phase Ib/2 study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and clinical activity of eq001 in subjects with newly diagnosed…EQ001 (ITOLIZUMAB (BMAB 600)) / PREDNISONEEQUILLIUM, INC.Pending

FDA Orphan Designations

Approved first, then open designations, newest first
DateDrugSponsorStatus
Sep 15, 2010MultistemProphylaxis of graft vs host diseaseAthersys, Inc.Designated

Medicines Authorised in the EU

Newest first
AuthorisedMedicineHolderEPAR
Mar 24, 2026Rezurockbelumosudil · orphanSanofi Winthrop IndustrieEMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.